Wells Fargo & Company Exicure, Inc. Transaction History

Wells Fargo & Company

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.53 - $0.84 $0 - $0	1 Added 1.67%	61 $0
Q4 2023 Feb 09, 2024	BUY	$0.37 - $0.75 $1 - $2	3 Added 5.26%	60 $0
Q3 2023 Nov 13, 2023	BUY	$0.71 - $1.36 $4 - $9	7 Added 14.0%	57 $0
Q2 2023 Aug 15, 2023	BUY	$0.85 - $1.44 $22 - $38	27 Added 117.39%	50 $0
Q3 2022 Nov 14, 2022	SELL	$1.53 - $8.5 $994 - $5,525	-650 Reduced 96.58%	23 $0
Q2 2022 Aug 12, 2022	BUY	$2.16 - $6.36 $1,453 - $4,280	673 New	673 $1,000

287K

Ticker XCUR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,962,580
Market Cap $91.2M
Description
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.